Syros Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript
Great. Good morning, everybody. Thank you for joining us again at the JMP Securities Life Science Conference. I'm Jason Butler, one of the biotech research analysts. Excited to start my morning off at least with Syros Pharmaceuticals.
Syros is a company developing novel therapeutics for primarily cancer indications and excited to be joined by the company's CEO, Nancy Simonian. So Nancy, thank you for being here and would love to just ask you to give a quick intro and a 30-second overview of Syros.
Great, Jason. Thank you so much for having us today. So Syros is a late-stage development company that's focusing on developing new standards of care for the frontline treatment of hematologic malignancies. We have two programs in three heme diseases, MDS, AML, and APL, all in targeted populations. We think they're very attractive opportunities where there's very high unmet medical need. We have multiple data catalysts coming up over the next 18 months and we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
